---
title: "MapLight Therapeutics, Inc. (MPLT) Gets a Buy from Jefferies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294388175.md"
description: "Jefferies analyst maintained a Buy rating on MapLight Therapeutics, Inc. today and set a price target of $25.00.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks In addition to Jefferies, MapLight Therapeutics, Inc. also received a Buy from H.C. Wainwright’s Ram Selvaraju in a report issued on July 28. However, on the same day, Morgan Stanley downgraded MapLight Therapeutics, Inc. (NASDAQ: MPLT) to a Hold."
datetime: "2026-07-30T15:26:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294388175.md)
  - [en](https://longbridge.com/en/news/294388175.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294388175.md)
generator: "portal-rs"
---

# MapLight Therapeutics, Inc. (MPLT) Gets a Buy from Jefferies

Jefferies analyst maintained a Buy rating on MapLight Therapeutics, Inc. today and set a price target of $25.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

In addition to Jefferies, MapLight Therapeutics, Inc. also received a Buy from H.C. Wainwright’s Ram Selvaraju in a report issued on July 28. However, on the same day, Morgan Stanley downgraded MapLight Therapeutics, Inc. (NASDAQ: MPLT) to a Hold.

### Related Stocks

- [MPLT.US](https://longbridge.com/en/quote/MPLT.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Catalyst4 acquires $50.07 million of MapLight Therapeutics common shares](https://longbridge.com/en/news/296276892.md)
- [MapLight Therapeutics prices USD 150 million PIPE at USD 11.38 a share](https://longbridge.com/en/news/295804908.md)
- [Piper Sandler Reaffirms Their Buy Rating on Akebia Therapeutics (AKBA)](https://longbridge.com/en/news/296105482.md)
- [Lowe’s Earns Buy Rating as Strong Earnings and Cash Generation Offset Lower-End Guidance](https://longbridge.com/en/news/296383656.md)
- [Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position](https://longbridge.com/en/news/296384188.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**